Omeros Corporation

Equities

OMER

US6821431029

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-06-14 pm EDT 5-day change 1st Jan Change
4.06 USD -4.02% Intraday chart for Omeros Corporation +5.18% +24.16%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Omeros Corporation Announces Executive Changes CI
Omeros Corporation announced that it expects to receive $92.1 million in funding CI
Health Care Flat as Momentum Wanes -- Health Care Roundup DJ
Transcript : Omeros Corporation, Q1 2024 Earnings Call, May 15, 2024
Omeros Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Tranche Update on Omeros Corporation's Equity Buyback Plan announced on April 1, 2024. CI
Omeros Corporation announces an Equity Buyback for $50 million worth of its shares. CI
Omeros Swings to Q4 Net Loss; Q1 Outlook Set MT
Omeros Corporation Provides Earnings Guidance for the First Quarter of 2024 CI
Transcript : Omeros Corporation, Q4 2023 Earnings Call, Apr 01, 2024
Omeros Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Omeros Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
North American Morning Briefing : Tech in Focus on -2- DJ
North American Morning Briefing : Investors -2- DJ
National Bank Raises DRI Healthcare Target to $22 on Omidria News, Guidance Increase MT
DRI Healthcare Trust Expands Royalty Entitlement on US Net Sales of Omidria, Updates Deployment and CAGR Guidance MT
Omeros Corporation(NasdaqGM:OMER) dropped from NASDAQ Biotechnology Index CI
North American Morning Briefing : Stock Futures -2- DJ
Transcript : Omeros Corporation, Q3 2023 Earnings Call, Nov 09, 2023
Omeros Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Omeros Corporation authorizes a Buyback Plan. CI
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting CI
Novartis drug candidate scores interim win in rare kidney disease trial RE
Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer CI
US Equity Markets Close Higher Monday on Expectations for Upbeat Q3 Earnings MT
Chart Omeros Corporation
More charts
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
More about the company
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
4.06
Average target price
-
Consensus
  1. Stock Market
  2. Equities
  3. OMER Stock
  4. News Omeros Corporation
  5. Omeros Swings to Q4 Net Loss; Q1 Outlook Set